CAR T-Cell kurapwa kune isiri-diki cell cancer yemapapu

Kurume 2024: CAR T-cell therapy inzira inogona kurapa cancer, kunyanya muhematological malignancies. Nekudaro, kushanda kwayo mumamota akasimba, akadai sekenza yemapapu, ishoma nekuda kwebundu microenvironment's immunosuppressive nature. Vatsvagiri vari kugadzira chizvarwa chinotevera cheCAR T maseru kuti vawedzere kupinda kwavo, kurarama, uye kushingirira mukati mezvakaipa. Miedzo yemakiriniki iri kuenderera mberi yekuongorora kuchengetedzeka uye kushanda kweCAR T-sero kurapwa mukenza yemapapu, paine mimwe mhedzisiro inovimbisa. Kupukunyuka kweAntigen, zvipingamupinyi zvekudzivirira, uye kukuvara-kwakavavarirwa kubva-bundu ndezvimwe zvezvinetso muCAR T-sero kurapwa kwegomarara remapapu. Injiniya CAR inovaka, kushandura iyo tumarara microenvironment, uye kushandisa masero eCAR T ari kure-pasherufu mamwe mazano ekugadzirisa matambudziko aya.

Chimwe chezvipatara zvinotungamira muChina chakabudirira kuyedza CAR T-Cell therapy mukati isina-diki kenza yemapapu kenza varwere. CAR T-Cell pamagomarara ese aya inoshanda kuvarwere mushure memamwe marapirwo akadai sekuvhiya, chemotherapy neradiotherapy asi vobva vatangazve.

Pazvirwere zvese, kenza yemapapu ine chiitiko chikuru uye huwandu hwerufu pasi rese. Kukura kwakasiyana-siyana kwemishonga yeimmunotherapeutic, kunyanya iyo inotarisa monoclonal antibodies, yakashandiswa mukurapa kwekiriniki yehutsinye panguva ino. immunotherapy nguva, kunyangwe ichine zvakawanda zvinokanganisa. Pamusoro pekushandiswa zvinobudirira kurwisa cancer yehematological, chimeric antigen receptor-modified T (CAR-T) masero akagadzirawo mikana mitsva ye immunotherapy yemapundu akasimba, akadai sekenza yemapapu. Kushaikwa kweakakodzera tumor-specific antigens, an immunosuppressive tumor microenvironment, yakaderera mwero weCAR-T cell kupinda mukati mebundu tishu, pamwe neasina chinangwa mhedzisiro, nezvimwe zvinoita kuti zviome kunanga. kenza yemapapu-specific antigens ane modified CAR-T masero. Zvichakadaro, nekuda kwekunetseka kwakawanda senge tumor lysis syndrome, neurotoxicity syndrome, uye cytokine release syndrome, kushandiswa kwekliniki kwemasero eCAR-T kuchiri kurambidzwa. Nechinangwa chekupa maonero matsva uye nzira dzezvidzidzo zvepre-kiriniki uye miedzo yekiriniki yeCAR-T cell therapy yekenza yemapapu, tinotsanangura chimiro chakakosha uye hunhu hwechizvarwa chemasero eCAR-T muongororo iyi, inopfupisa iyo yakajairwa bundu-inosanganiswa. maantigen, uye simbisa matambudziko aripo.

Chimiro cheCARS

Kubva payakavambwa, kushandiswa kweCAR muT-cell therapy kwapfuura nezvizvarwa zvina zvinodzokororwa, izvo zvese zvinoenderana neCAR's intracellular signal domains. Chizvarwa chekutanga cheCAR chaive nechiitiko chisina kusimba uye ipfupi in vivo yekupona nguva nekuti ivo vaingove neiyo antigen yekuziva chiratidzo. Iyo chiratidzo chekushandura nzvimbo yechizvarwa chechipiri uye chechitatu maCAR, zvichiteerana, yaive neayo uye maviri mamorekuru anodhura. Idzi shanduko dzakaitwa kuitira kuwedzera T cell kupona, cytotoxicity, uye kuwanda. Iyo co-stimulatory molecules muCARs yakagadziridzwa, iyo yakavandudza CAR-T cell performance. 4-1BB kana CD28 ndiwo maviri echizvarwa chechipiri co-stimulatory domains anonyanya kushandiswa. Uyezve, cytotoxicity, kugadzirwa kwe cytokine, uye T cell activation zvose zvakaratidzwa kuva nani neDNAX-activating protein 10 (DAP10). Kubva pane isiri-diki yekenza yemapapu (NSCLC) maseru mitsara, kunonoka kwekutanga kenza yemapapu kukura uye kuwedzera anti-bundu chiitiko kwakaratidzwa mune vivo mhuka mhando dzekenza yemapapu emunhu xenotransplantation. Pro-inflammatory cytokines uye co-stimulating ligands yakawedzerwa muchizvarwa chechina CAR-T dhizaini kuti ibatsire maT-cells kupinza uye kupfuudza hutsinye hweTME's suppressive properties.

Amplification uye anti-tumor efficacy yeCAR-T masero akaratidzirwa kuti anovandudzwa nekuvandudza extracellular module structure kuwedzera kune intracellular signal transduction modules. Sekureva kwaQin et al., iyo imwe-chain chain fragment (scFv), inosunga uye inokurudzira kuwedzera, kutama, uye kupinda kweboka rekusiyanisa 4 (CD4) + CAR-T masero, akaitwa zvakanyanya kuchinjika nekuwedzera. yehinge structure. Kunyangwe chizvarwa chechipiri masero eCAR-T achiramba ari nzira yakajairwa yekushandiswa kwekurapa, magadzirirwo ezvimiro zveCAR ari kugara achivandudzwa uye akakosha kuCAR-kushanda. T's

CAR T-Cell kurapwa mukenza yemapapu uye inonangwa antigen

Kana iyo tarisiro-antigen inoratidzwa chete pamasero egomarara kana kuwandisa pane ese kana mazhinji ekenza yemapapu maseru tichienzanisa neakajairwa maseru, ichi ndicho chakanyanya kunangwa chekurapwa kweCAR-T cell. Kunyangwe huwandu hukuru hwema tumor-anobatanidza maantigens (TAA) akawanikwa mune asiri madiki maseru emapapu cancers (NSCLCs), mashoma emaantigen aya akatariswa zvakanyanya neCAR-T masero (8). Pamusoro pezvo, mamwe eaya anotangwa-maantigen anoratidzwawo zvisina kusimba mumatishu ane hutano, achipa mamwe masero eCAR-T kugona kurova maseru ane hutano.

Epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), mesothelin (MSLN), prostate stem cell antigen (PSCA), mucin 1 (MUC1), carcinoembryonic antigen (CEA), tyrosine kinase-yakafanana nenherera receptor ( ROR1), programmed death ligand 1 (PD-L1), uye CD80/CD86 ndezvimwe zvezvinangwa zviri kudzidzwa kuCAR.

Murwere wegomarara remapapu ari kurapwa neCAR T-Cell

Mbudzi we2009, murwere akawana mapapu ekuruboshwe uye akavhiyiwa kenza yemapapu ekuruboshwe. Pathology: mapapu adenocarcinoma;
Kubva muna Ndira 2013 kusvika muna Jan 2017, metastases matatu ehuropi akaitika, uye kuvhiyiwa uye kurapwa kwemwaranzi kwakapihwa zvakatevedzana nekutonga kwakashata;
Kubva munaKurume 2017 kusvika Gunyana 2017, yehuropi metastases, mesoCAR-αPD1 maseru anoratidza PD-1 antibody akapihwa 6 makosi ekurapa. Mushure mekurapwa, PR yakaongororwa uye mamota akadzikira zvakanyanya aine mashoma chete masara.

CAR T-Cell kurapa muChina

CAR-T Cell kurapwa muChina iri kukura nokukurumidza zvikuru. Results of CAR T-cell kurapa muChina uye huwandu hwekurapa huri pakati pezvakanakisa pasi rose parizvino. Kune anopfuura mazana matatu ekiriniki miedzo iri kuitika mukati China yeCAR T Cell therapy. China iri pakati penyika dzekutanga kupa CAR T Cell kurapwa mushure USA & UK. Panyaya yehuwandu hweCAR-T miedzo yekiriniki, China ndeyechipiri kuUSA, ichinyoresa zvingangoita makumi matatu nenhatu muzana yemiedzo pasi rese. Huwandu hweCAR T-cell therapies mukuvandudza kwekiriniki hwakatenderera mumakore achangopfuura. Parizvino, muChina, kune anopfuura mazana matatu ari kuramba achiyedzwa ekiriniki muhematologic malignancies pamwe nemamota akasimba.

Kuongorora kwakadzama kweChina uye kubudirira mukutsvaga maantigen matsva, optimization yeCAR chimiro, cocktail yeCAR-T kurapwa, musanganiswa kurapa, uye kuwedzera kweCAR-T cell application, zvinoreva kuti parizvino tave padanho rekuchinja muCAR- T kurapa. US FDA yakabvumira CAR T Cell kurapwa yekudzokazve B Acute lymphoblastic leukemia, lymphoma & multiple myeloma. China ichangobva kubvumidza CAR T-Cell kurapwa kune mamwe magomarara akasimba. Varwere vanobva kumativi ese enyika vanogona kubatsirwa nebudiriro iyi.

Unogona kuda kuverenga: CAR T-Cell kurapa muChina

Chii chinonzi CAR T-Cell therapy (Chimeric antigen receptors)?

CAR T-Cell therapy imhando ye immunotherapy inoshandisa akagadziridzwa T-masero ari chikamu che immune system yedu kurwisa cancer. Muenzaniso wevarwere T masero anounganidzwa kubva muropa, zvino inogadziriswa kuti ibudise zvivako zvakakosha zvinonzi chimeric antigen receptors (CAR) pamusoro pavo. Kana aya masero akagadziridzwa eCAR apinzwazve mumurwere, aya masero matsva anorwisa chaiyo antigen uye anouraya bundu maseru.

CAR T-Cell kurapwa inoshanda sei?

CAR T-cell therapy inotora rubatsiro kubva ku immune system yemuviri kurwisa nekuuraya maseru egomarara. Izvi zvinoitwa nekubvisa mamwe masero akatsanangurwa kubva muropa remurwere, achiachinja murabhoritari uye achiapinzazve mumurwere. CAR T-cell therapy yakaburitsa mhedzisiro inokurudzira mukati Asiri-Hodgkin lymphoma uye nokudaro yakatenderwa neFDA.

Ndivanaani vakakodzera kukwikwidza kuCAR T-Cell kurapwa?

Parizvino FDA yakabvumidza CAR T-Cell kurapa kune mamwe marudzi ehasha uye refractory Non-Hodgkin lymphoma uye kudzoka uye kuramba. acute lymphoblastic leukemia. Murwere anofanirwa kutumira mishumo yekurapa yakazara kuti aone kushandiswa kweCAR T-Cell kurapwa kwake.

Inosanganisira maitiro eCAR T-cell therapy:

1. Varwere vane CD19+ B-cell Lymphoma (Anenge maviri asati asangana chemotherapy regimens)

2. Kuva ane makore matatu kusvika makumi manomwe nemashanu ekuberekwa

3. ECOG zvibodzwa ≤2

4. Vakadzi vane mikana yekuzvara vana vanofanira kuongororwa weti kuti vane pamuviri uye voonekwa kuti havana kubatwa here vasati varapwa. Vose varwere vanobvumirana kushandisa nzira dzakavimbika dzekudzivirira pamuviri panguva yekuedzwa uye kusvika pakutevera kwenguva yekupedzisira.

Kuregera maitiro eCAR T-cell kurapa:

1. Intracranial neBP kana kufenda

2. Kutadza kufema

3. Yakaparadzirwa intravascular coagulation

4. Hematosepsis kana Utachiona husingadzoreki hunoshanda

5. Chirwere cheshuga chisingadzoreki

Kubatsira kweCAR T-Cell kurapa

1. > 5000 CAR T makesi anoitwa nachiremba ane hunyanzvi.
2. Zvipatara muChina zvakagadzira mamwe maCAR T Cell mhando dzinosanganisira CD19 & CD 22 ipapo chero imwe nyika pasi.
3. China iri kuitisa zvinopfuura mazana matatu emakiriniki ekuedzwa paCAR T Cell therapy. Kupfuura chero imwe nyika pasi.
4. Clinical mhedzisiro yeCAR T Cell yakafanana neiyo muUSA kana chero imwe nyika uye dzimwe nguva zvirinani.

Kurapa kweCAR T-Cell kurapa

• Zadzisa ongororo yemurwere
• T-cell kuunganidzwa kubva mumuviri
• T-maseru anobva agadzirwa murabhorari
• MaT-Cell akagadzirwa nemajini anobva awedzerwa nekushandisa kukura mumarabhoritari. Aya maseru anotonhorwa otumirwa kunzvimbo dzinorapa.
• Asati akanganisa, murwere anogona kupihwa chemotherapy yekenza yavo. Izvi zvinobatsira kurapwa kurapa nenzira iri nani.
• Nguva pfupi yapfuura chemotherapy CAR T-Masero inopindirwa nemaitiro akafanana nekuisirwa ropa.
• Pane mwedzi 2-3 wekudzora nguva yemurwere.

Nguva yakatarwa yeCAR T-Cell kurapa

1. Kuongorora & kuyedza: vhiki imwe

2. Pre-kurapwa & T-Cell Kuunganidzwa: vhiki imwe

3. Kugadzirira kweT-Cell & kudzoka: mavhiki maviri-matatu

4. 1st Kubudirira kuongorora: vhiki nhatu

5. 2nd Effectiveness analysis: mavhiki matatu.

Side mhedzisiro yeCAR T-Cell kurapa

Iyo yakajairwa mhedzisiro mhedzisiro yeCAR T-cell kurapa inosanganisira:

• Cytokine kuburitsa chirwere
  Mune zvimwe zviitiko, varwere vanogona kuve nezviratidzo zvakaita sefuruwenza senge fivha, kutonhora, kutemwa nemusoro, kuda kurutsa, kurutsa, zvigwere zvakasununguka, uye kurwadziwa kwemhasuru kana majoini. Zvinogonawo kukonzera kuderera kweBP, kunetseka kufema, uye kurova kwemwoyo nekukurumidza. Izvi zvinokonzerwa nekusunungurwa kwema cytokines nemasero ekudzivirira panguva yeCAR T-cell therapy. Zviratidzo izvi zvinowanzova zvinyoro, asi zvinogona kunge zvakakomba uye zvinotyisidzira hupenyu kune vamwe varwere.
• Zviitiko zve Neurological
  Zviitiko zveeurological zvinogona kuitika uye zvinogona kuve zvakakomba mune vamwe varwere. Zviitiko zvakadaro zvinosanganisira encephalopathy (kukuvara kwehuropi uye kusashanda zvakanaka), kuvhiringidzika, kunetsekana kutaura, kushushikana, kufenda, kukotsira, kwakachinja mamiriro ekuziva uye kurasikirwa kwechiyero.
• Neutropaenia uye Anemia
  Vamwe varwere vanogona kukura neutropenia kana yakaderera chena cell count. Saizvozvo, anemia kana kuderera kwemasero matsvuku eropa anogonawo kuitika nekuda kwekurapa uku.
  .
  Sezvineiwo, mazhinji eaya mhedzisiro anowanzo gadzirisa ari ega kana anogona kutariswa nekushandiswa kwemishonga.

Inoshanda zvakadii CAR T-Cell kurapa?

CAR T-cell kurapwa kwekurapa kwe lymphoma uye mamwe magomarara eropa aratidza mhedzisiro inovimbisa. Kubva CAR T-cell kurapwa, varwere vazhinji vaive vambodzokera kumashure mamota eropa aive nemhedzisiro inovimbisa uye pasina humbowo hwegomarara. Yakabatsirawo mukudzoreredzwa kwevarwere vakambotadza kupindura mishonga yechivanhu yegomarara.

Zvisinei, zvidzidzo zvenguva yakareba zvevanhu vakawanda vane varwere zvinodiwa kuti zvibatsire kushanda kwekurapa uku. Kuedza kukuru-kwechiyero kwaizobatsirawo mukuona mukana wemhedzisiro uye nzira dzakakodzera dzekugadzirisa nazvo.

Marii inodiwa neCAR T-Cell therapy?

China mutungamiri wepasi rose weCAR-T cell therapy & BMT. Kusvika parizvino kune anopfuura mazana matatu eCAR-T cell ekiriniki miedzo irikuitika. Mushonga weCAR-T wekuChina ndiwo wakanyanya bhajeti pasi rose. Nekuti iyo CAR-T cell kugadzirira ndeye mahara izvozvi! Varwere vanongofanira kubhadhara kurapwa & masevhisi. Mutengo wese wekurapwa unenge uri $300-$60,000.

Verenga zvakare izvi: CAR T Cell kurapa muIndia 

Ndingatora sei CAR T-Cell kurapwa muChina?

Murwere anogona kufonera +91 96 1588 1588 kana email ku cancerfax@gmail.com neruzivo rwemurwere uye mishumo yekurapa uye ticharonga maonero echipiri, chirongwa chekurapa uye fungidziro yemari.